Skip to main content
. Author manuscript; available in PMC: 2011 Sep 15.
Published in final edited form as: J Immunol. 2010 Aug 13;185(6):3740–3749. doi: 10.4049/jimmunol.1001231

FIGURE 6.

FIGURE 6

MV activate p38 MAPK and NF-κB pathways. A, BMDM were left non-treated or were treated with 1 μg/ml LPS or 25 μg protein equivalents of MV for 2, 10, 30, or 60 minutes. Expression of phosphorylated p38 (p-p38) and total p38 (p38) was evaluated via Western blot. Data is representative of repeat experiments. B, BMDM were treated with 25 μg protein equivalents of MV with or without additional treatment of the phosphorylated p38 inhibitor SB203580 at either 1 μM, 10 μM, or 50 μM, or were left non-treated for 18 hours. The histogram indicates surface CD86 MFI means and ± SEM of n=3. The statistical comparison is made to 25 μg MV alone treated BMDM. C, RAW264.7 macrophages expressing luciferase under control of an NF-κB promoter were treated with 1 μg/ml LPS, 2.5, 25, or 75 μg protein equivalents of MV for 1, 4, or 18 hours. The fold change over non-treated cells is shown. The histogram indicates fold change means ± SEM of n=3. The statistical comparison is made to the 1 hour fold change value for each respective treatment.